Tessera Therapeutics Lays Off 90 Employees Amid Clinical Study Launch
SOURCENews reportView the filing ↗
What we know
Based on news reporting.
Summary
Tessera Therapeutics, a gene editing startup, has announced the layoff of 90 employees as it embarks on its first clinical study. This decision comes as part of the company's strategic adjustments during a critical phase of development. The layoffs reflect the company's efforts to streamline operations and focus resources on advancing its clinical initiatives. While the specific departments affected were not detailed, this move indicates a significant shift in the company's workforce strategy. The layoffs highlight the challenges faced by startups in the competitive biotech landscape.
Tessera Therapeutics cut 90 jobs as of January 8, 2026.
That is roughly 41.9% of the 215 people Tessera Therapeutics employs.
LayoffTalk has tracked 10 layoff events at Tessera Therapeutics since November 2025, including 262 jobs documented in official WARN filings, with 3 additional events known from news reporting.
Comments (0)
Anonymous by default. Be kind — people reading this may be going through it right now.
No comments yet. Be the first to share your thoughts.
Affected by this?
Share your story anonymously — it helps others reading this feel less alone.
Share your story →More layoffs at Tessera Therapeutics
Recent tracked events at this company.